Phreesia saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 66 to 73.
Can You Really Time The Stock Market?
This exclusive rating from Investor's Business Daily identifies price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the best stocks often have an 80 or higher RS Rating in the early stages of their moves. See if Phreesia can continue to rebound and hit that benchmark.
Phreesia is building a consolidation with a 30.53 buy point. See if the stock can clear the breakout price in volume at least 40% higher than normal.
Phreesia reported 0% EPS growth in the latest quarterly report. Revenue increased 15%.
The company holds the No. 7 rank among its peers in the Computer Software-Medical industry group. Veeva Systems Cl A, OptimizeRx and Waystar Holding are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
